Shionogi Consolidates Sleep Medicine Position via USD 150 Million Acquisition of Apnimed's SASS Joint Venture Stake
Shionogi & Co., Ltd. has entered a definitive agreement to acquire Apnimed, Inc.'s 50% ownership of the Shionogi-Apnimed Sleep Science, LLC (SASS) joint venture for USD 150 million in cash payments plus tiered royalties, bringing the sleep disorder-focused entity fully under Shionogi's control. The transaction allows Apnimed to strengthen its balance sheet as it prepares to submit its NDA for Apnimed AD109, a first-in-class oral combination therapy for obstructive sleep apnea, to the FDA in the second quarter of 2026.
Deal Structure and Financial Terms
The SASS joint venture $150M deal comprises a USD 100 million upfront cash payment and a USD 50 million milestone payment contingent on a development milestone related to SASS-002 (sulthiame), a carbonic anhydrase inhibitor acquired from Desitin Arzneimittel GmbH in April 2025. Apnimed also retains tiered royalties on future commercial sales of any products arising from SASS intellectual property. The transaction is structured entirely in cash with no equity component and is expected to close in the second quarter of 2026. Apnimed retains exclusive rights to AD109, its wholly-owned lead asset, which has completed two Phase 3 clinical trials for the treatment of mild, moderate, and severe OSA.
The Apnimed Shionogi joint venture was originally established in November 2023 as a 50/50 entity combining Shionogi's small molecule drug discovery capabilities with Apnimed's translational research expertise in sleep-disordered breathing. Shionogi's acquisition of full ownership consolidates its control over the SASS pipeline, including sulthiame and any additional undisclosed early-stage programs.
Sulthiame and the SASS Platform
The core identified asset within SASS is sulthiame, a differentiated carbonic anhydrase inhibitor that enhances ventilatory drive during sleep. Sulthiame has completed Phase 2 trials for OSA in Europe (the FLOW study) and holds approvals for non-sleep indications in several countries outside the United States. Its mechanism of action is distinct from AD109's noradrenergic and antimuscarinic approach, targeting respiratory chemosensitivity rather than upper airway neuromuscular tone. This mechanistic differentiation positions SASS to develop a complementary pharmacological approach to OSA that does not compete directly with AD109 obstructive sleep apnea treatment.
The broader SASS platform was designed to advance multiple pharmacological solutions for sleep disorders. However, beyond sulthiame, specific additional assets or research programs have not been publicly disclosed, representing a gap in the available information.
AD109 and Apnimed's Path to NDA Submission
Apnimed AD109 is a once-daily oral combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. The combined pharmacology targets the hypoglossal motor nucleus to prevent upper airway collapse during sleep, addressing the neuromuscular root cause of OSA. Phase 3 data demonstrated a 46.8% reduction in the apnea-hypopnea index compared to 6.8% for placebo. The Apnimed NDA submission is expected in the second quarter of 2026, coinciding with the expected close of the SASS transaction. If approved, AD109 would represent a paradigm shift in OSA oral drug treatment, a disease historically managed through CPAP devices and surgical interventions. An estimated 80 million people in the United States and one billion worldwide are affected by OSA.
Competitive Landscape and Industry Benchmarks
The OSA pharmacotherapy space has seen accelerating deal activity. Kyorin Pharmaceutical licensed BAY-2925976, a Phase II OSA candidate, from Bayer in December 2024 for EUR 15 million upfront plus milestones and royalties totaling over EUR 85 million. Eli Lilly secured FDA approval for tirzepatide (Zepbound) in OSA in 2024, validating the commercial thesis for pharmacological OSA treatment through a weight-mediated mechanism. Incannex Healthcare is advancing IHL-42X, a dronabinol and acetazolamide combination sharing the carbonic anhydrase inhibition mechanism with sulthiame, through Phase 2. Mineralys Therapeutics cleared an IND for lorundrostat in OSA with hypertension in January 2025.
Shionogi's broader acquisition trajectory reinforces the strategic rationale. The company agreed to acquire Radicava global rights from Tanabe Pharma for USD 2.5 billion in December 2025 and completed the acquisition of Torii Pharmaceutical and Akros Pharma from Japan Tobacco for approximately USD 1.1 billion in 2025. Combined deal value exceeding USD 3.6 billion in 2025 alone signals a fundamental strategic pivot from Shionogi's traditional infectious disease base toward rare disease, sleep medicine, and diversified therapeutics.
Strategic Outlook
The convergence of multiple pharmacological mechanisms entering clinical development for OSA reflects growing recognition that the disease's heterogeneous pathophysiology requires multiple therapeutic approaches. Shionogi's consolidation of SASS positions it to develop sulthiame's respiratory drive mechanism independently while Apnimed advances AD109's neuromuscular approach, creating two mechanistically complementary oral therapies for a condition affecting over one billion people globally with limited pharmacological options. Apnimed's monetization of its joint venture stake without dilutive financing, while retaining royalty exposure and full AD109 ownership, represents a capital-efficient strategy to fund its transition from clinical-stage company to commercial entity.
Spot something wrong? Report an issue with this article